Citius Pharmaceuticals Issues May 2020 Shareholder Letter
– Company highlights exclusive option to license novel stem-cell therapy for ARDS related to COVID-19 from Novellus, Inc. – Status of pivotal Ph. 3 trial evaluating Company’s lead-product Mino-Lok® as an antibiotic lock solution used […]
